

1 **Refining “long-COVID” by a prospective multimodal evaluation of patients with long-**
2 **term symptoms related to SARS-CoV-2 infection**

3
4 **Running title: Multimodal evaluation of “long-COVID”**

5
6 Marc Scherlinger (0000-0002-9453-5895)*^{1,2}, Renaud Felten*^{1,2}, Floriane Gallais*³,
7 Charlotte Nazon³, Emmanuel Chatelus^{1,2}, Luc Pijnenburg^{1,2}, Amaury Mengin⁴, Adrien Gras⁴,
8 Pierre Vidailhet⁴, Rachel Arnould-Michel^{1,2}, Sabrina Bibi-Triki⁵, Raphaël Carapito⁵, Sophie
9 Trouillet-Assant⁶, Magali Perret⁶, Alexandre Belot⁶, Seiamak Bahram⁵, Laurent Arnaud^{1,2,5},
10 Jacques-Eric Gottenberg^{1,2,7}, Samira Fafi-Kremer^{#3,5} & Jean Sibia^{#, 1,2,5}

11
12 * **Participated equally in the study.**

13 # **Participated equally in the study.**

14
15 **Affiliations:**

16 *1 Rheumatology Department, Centre Hospitalier Universitaire de Strasbourg, 1 avenue*
17 *Molière, 67098 Strasbourg, France*

18 *2 Centre National de Référence des Maladies Auto-Immunes et Systémiques Rares, Est/Sud-*
19 *Ouest (RESO), France*

20 *3 Virology diagnostic laboratory, Centre Hospitalier Universitaire de Strasbourg, 3 Rue*
21 *Koeberlé, 67000 Strasbourg, France*

22 *4 Psychiatry department, Centre Hospitalier Universitaire de Strasbourg, 1 avenue Molière,*
23 *67098 Strasbourg, France*

24 *5 Laboratoire d’ImmunoRhumatologie Moléculaire, Institut national de la santé et de la*
25 *recherche médicale (INSERM) UMR_S 1109, Institut thématique interdisciplinaire (ITI) de*
26 *Médecine de Précision de Strasbourg, Transplantex NG, Faculté de Médecine, Fédération*
27 *Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg*
28 *(FMTS), Université de Strasbourg, Strasbourg, France.*

29 *6 National Reference centre for Rare rheumatic and AutoImmune diseases in childrEn*
30 *RAISE, Hospices Civils de Lyon, CIRI, Centre International de Recherche en Infectiologie,*
31 *Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-*
32 *69007, Lyon, France*

33 *7 IBMC, UPR3572, CNRS, Strasbourg, France*

34
35 **Word count : 2936**

36 **Figure count : 4**

37 **Table count: 2**

38
39 **Keywords:** SARS-CoV-2; long-COVID; patient perspective; pain; disability

40 **Corresponding authors:** Prof. Jean Sibia, M.D. *Ph.D.* and Marc Scherlinger, M.D. *Ph.D.*

41 Centre national de référence maladie auto-immunes et systémiques rares Est/Sud-Ouest

42 (RESO), Service de Rhumatologie du CHU de Strasbourg. 1 Avenue Molière, 67200

43 Strasbourg Cedex. Telephone number: + 33 3 88 12 84 74. Fax number: + 33 3 88 12 82 90

44 *Email : jean.sibia@chru-strasbourg.fr and marc.scherlinger@chru-strasbourg.fr*

45 **Acknowledgments:** We thank all patients who agreed to take part in the study. We thank
46 Valle Meyer for her precious help in planning the study and patient communication. We also
47 thank COVID-HUS for its support.

48 **Conflicts of interest:** SFK has received speakers fees from BMS and Roche.

49

50

51 **Key points:**

52

53 • Among 30 consecutive patients reporting persistent symptoms (median 6 months)
54 self-attributed to COVID-19, pain, fatigue and disability were reported in virtually all
55 patients.

56 • More than one third of patients suffer from psychological disorders such as anxiety,
57 depression and/or post-traumatic stress disorder, regardless of SARS-CoV-2
58 immunity.

59 • At the time of evaluation, only 50% of patients had cellular and/or humoral sign of a
60 past SARS-CoV-2, and serology positivity varied depending of the kit used.

61 • Exhaustive clinical, biological and immunological evaluations failed to find an
62 alternative diagnosis, or to identify specific cytokine signature including type I
63 interferon.

64

65

66 **Abstract**

67

68 **Background:** COVID-19 long-haulers or “long-COVID” represent 10% of COVID-19
69 patients and remain understudied.

70 **Methods:** In this prospective study, we recruited 30 consecutive patients seeking medical
71 help for persistent symptoms (> 30 days) attributed to COVID-19. All reported a viral illness
72 compatible with COVID-19. The patients underwent a multi-modal evaluation including
73 clinical, psychological, virological, specific immunological assays and were followed
74 longitudinally.

75 **Results** The median age was 40 [interquartile range: 35-54] and 18 (60%) were female. After
76 a median time of 152 [102-164] days after symptom onset, fever, cough and dyspnea were
77 less frequently reported as compared with the initial presentation, but paresthesia and burning
78 pain emerged in 18 (60%) and 13 (43%) patients, respectively. The clinical examination was
79 unremarkable in all patients although the median fatigue and pain visual analogic scales were
80 7 [5-8] and 5 [2-6], respectively.

81 Extensive biological studies were unremarkable, as were multiplex cytokine and ultra-
82 sensitive interferon- α 2 measurements. At this time, nasopharyngeal swab and stool RT-PCR
83 were negative for all tested patients. Using SARS-CoV-2 serology and IFN- γ ELISPOT, we
84 found evidence of a previous SARS-CoV-2 infection in 50% (15/30) of patients, with
85 objective evidence of lack or waning of immune response in two. Finally, psychiatric
86 evaluation showed that 11 (36.7%), 13 (43.3%) and 9 (30%) patients had a positive screening
87 for anxiety, depression and post-traumatic stress disorder, respectively.

88 **Conclusions** Half of patients seeking medical help for long-COVID lack SARS-CoV-2
89 immunity. The presence of SARS-CoV-2 immunity did not cluster clinically or biologically
90 long haulers, who reported severe fatigue, altered quality of life, and exhibited psychological
91 distress.

92 ***Introduction***

93 After SARS-CoV-2 infection, some patients may continue to experience symptoms for
94 months (1), a condition called “long-COVID” or “COVID-19 long-haulers” (2). These long-
95 term symptoms contribute to the worldwide COVID-19 burden and have been extensively
96 communicated by the patients and some physicians (3,4). Long-COVID manifestations are
97 clinically diverse, and their underlying mechanisms are likely to be multiple. Patients who
98 underwent long hospitalization because of severe disease may exhibit lung or heart chronic
99 injury due to the severe immune response (5,6), micro- or macrovascular thrombotic
100 neurological complications (7), and/or physical deconditioning (8). Indeed, a recent cohort
101 study found that among 1733 hospitalized COVID-19 patients, 76% reported at least one
102 symptom after 6 months, and objective pulmonary abnormalities were found in more than
103 20% (9). However, these pathological mechanisms are less likely to explain the
104 manifestations in patients with initially non-severe COVID-19 who experience long-lasting
105 symptoms. Although 10% of COVID-19 patients may show chronic symptoms (>12 weeks)
106 (10), only scarce data are available on the clinical presentation, biological characteristics and
107 overall prognosis of such patients (11,12). Moreover, the virological definition of the long-
108 COVID entity in terms of serology and other specific immunological assays is still not
109 precisely established (11,13).

110 The aim of our study was to refine the clinical and biological characteristics of long-COVID
111 by conducting a multimodal evaluation of consecutive patients seeking medical help for
112 persistent symptoms attributed to COVID-19 (long-COVID).

113

114 ***Methods***

115 *Patients and ethical considerations*

116 We included 34 consecutive patients seeking medical help for persistent symptoms attributed
117 to COVID-19 for a systematic prospective study. Patients were recruited in the “Grand-Est”
118 region of France, the area with the highest incidence of SARS-CoV-2 infection during the
119 first epidemical wave in France (February to April 2020) (14). Information about a long-
120 COVID consultation in our tertiary center was advertised through local media and social
121 networks, and consulting patients were then asked to participate in the study. All patients
122 provided written informed consent. Age-matched patients with a history of non-severe
123 COVID-19 (positive humoral and cellular response) without persistent symptoms were
124 controls for the immunological assays. This study is part of the “COVID-HUS” study, which
125 was approved by the ethics committee of the University Hospital of Strasbourg (NCE–2020–
126 51).

127

128 *Medical evaluation*

129 All patients were evaluated at our reference center for rare systemic and autoimmune
130 diseases. Five physicians (MS, RF, EC, LP and JS) conducted the clinical evaluation with a
131 physical examination and a standardized questionnaire on medical and SARS-CoV-2-related
132 infection history. Dedicated questionnaires were used to evaluate subjective symptoms: DN4
133 for neuropathic pain (15), Fibromyalgia Rapid Screening Tool (FiRST (16)) and visual
134 analog scales for fatigue/pain/dryness. Additionally, patients underwent systematic blood
135 testing to rule out alternative diagnoses (full list in supplementary file 1).

136

137 *Virologic and immunologic evaluation*

138 Blood samples were collected at the same time as the clinical evaluation for immuno-
139 virologic assays. The testing included extensive serology evaluation with 4 commercial
140 assays. One lateral flow assay tested for the receptor binding 2 (RBD) of the spike protein as
141 an antigenic source (Biosynex BSS IgM/IgG assay), and two enzyme-linked immunosorbent
142 assays (ELISA) targeted the RBD (Wantai total antibody) and the S1 domain (Euroimmun
143 IgG). Finally, ELISA was used to detect anti-nucleocapsid (anti-N) IgG (Abbott Architect
144 IgG). To explore the SARS-CoV-2-specific T-cell response, heparin-anticoagulated blood
145 tubes were collected for interferon gamma (IFN- γ) enzyme-linked immunospot (ELISPOT)
146 assay. Peripheral blood mononuclear cells were isolated by using Ficoll-Paque gradient, and
147 CD3⁺ cell frequencies were measured by flow cytometry. Anti-IFN- γ antibody-coated wells
148 (UCytech) were seeded with 200,000 CD3⁺ cells per well. Cells were stimulated in duplicate
149 with overlapping 15-mer peptide pools spanning SARS-CoV-2 structural proteins (spike
150 protein [S1 and S2], nucleoprotein, membrane and envelope proteins) and accessory proteins
151 (NS3, NS7A, NS8, NS9B) as well as the spike glycoprotein of human coronaviruses 229E
152 (ES1, ES2) and OC43 (OS1, OS2) (PepMix, JPT Peptide Technologies). Culture medium
153 was a negative control and phytohemagglutinin (PHA) a positive control. Peripheral blood
154 mononuclear cells were cultured overnight (20 ± 4 hr) before enzymatic revelation of IFN- γ
155 capture (UCytech). Spots were counted by using an ELISPOT reader (AID) and results are
156 expressed as mean number of spot-forming units/ 10^6 CD3⁺ cells after subtraction of the
157 background value. Positivity was defined as a T-cell response ≥ 3 times the standard
158 deviation of the negative controls. To complete the immunological evaluation, IFN- $\alpha 2$ (with
159 Single Molecule Array; SIMOA, Quanterix (17)) and cytokines (with a custom multiplex
160 cytokine assay; Luminex Thermo Fisher) were measured from serum samples.

161

162 *Psychological evaluation*

163 A standardized interview was conducted by a clinical psychologist (R.A-M). The interview
164 aimed at evaluating psychiatric history and treatments, presence of sleep issues and increase
165 of toxic or anxiolytic use. The impact of the COVID-19 pandemic on quality of life was
166 assessed by using the Medical Outcomes Study 36-item Short-form (SF-36) and Health
167 Assessment Questionnaire (HAQ). Patients' perspectives on the pandemic crisis were
168 assessed. Finally, validated translated questionnaires were used to screen for
169 anxiety/depression (Hospital Anxiety and Depression Scale [HADS-A/D]) and post-traumatic
170 stress disorder (PTSD checklist [PCL-5] for the Diagnostic and Statistical Manual of Mental
171 Disorders, Fifth edition [DSM-5]). Positive screening for these mental disorders was
172 confirmed with a score ≥ 10 for HADS-Anxiety, ≥ 7 for HADS-Depression (18), and ≥ 31 for
173 PCL-5 (19).

174

175 Statistics

176 Quantitative data are reported with median (interquartile range [IQR]) and were compared by
177 non-parametric Mann-Whitney test. Categorical data are reported with number (%) and were
178 compared by chi-square or Fisher exact test, as appropriate. To compare initial and persistent
179 clinical features, McNemar's test was used with Bonferroni's correction for multiple testing.
180 Statistical analyses involved using GraphPad Prism 7.0. $P < 0.05$ was considered statistically
181 significant.

182

183

184 **Results**

185 *Patients*

186 A total of 34 consecutive patients seeking help for persistent symptoms attributed to COVID-
187 19 visited to our center between June and August 2020; 30 were included in the study.
188 Reasons for non-inclusion were refusal of physical consultation because of geographical
189 distance (n=3), spontaneous improvement of the condition (n=1). In total, 60% were women
190 (18/30) and the median age was 40 years (IQR 35-54). The cohort included 2 married
191 couples, and other patients were unrelated. Before the initial presentation, none of the patient
192 reported chronic pain nor the use of analgesics. Other characteristics are in **Table 1**.

193

194 *Initial presentation*

195 All patients declared a viral illness compatible with COVID-19. Initial symptoms occurred
196 between 1 February and 9 April 2020 and were mainly characterized by fever (60%), myalgia
197 (76.7%), cough (73.3%) and anosmia (43.3%) (**Figure 1**). Among 9 patients who underwent
198 nasopharyngeal SARS-CoV-2 RT-PCR within 5 weeks after symptom onset, 55.6% (5/9) had
199 a positive result and all RT-PCR tests conducted after this time were negative (n = 11). Seven
200 patients consulted in the emergency department, and one was hospitalized in a conventional
201 hospital unit to receive oxygen for 7 days, without specific treatment. All other patients were
202 cared for at home. A total of 13 patients were prescribed treatments: 2 received
203 hydroxychloroquine 400 mg/day, 4 prednisone 1 mg/kg for 5-7 days, 8 antibiotics
204 (azithromycin, n = 6; amoxicillin, n = 2) and 2 low-dose aspirin. The other 17 patients
205 received only symptomatic treatment (acetaminophen).

206

207 *Persistent clinical features*

208 Patients were clinically evaluated after a median of 152 days (IQR 102-164) after the
209 reported initial symptom onset. Seventeen (56.7%) reported a resolution of initial symptoms
210 after a median of 21 days (IQR 15-33), followed by a resurgence after a median of 21 days
211 later (IQR 15-44). Conversely, the 13 other patients had no free-symptom intervals. Persistent
212 symptoms had a cyclical pattern in 28 (93.3%) patients and were mostly represented by
213 fatigue, myalgia and thoracic oppression (**Figure 1A**). Fever, shivering and cough were
214 significantly less frequent as compared with the initial presentation ($p < 0.005$ for all; **Figure**
215 **1A**). Fatigue was severe for most patients and rated at a median of 7 (IQR 5-8) on a 10-point
216 scale, with pain rated at 5 (IQR 2-6).

217 Overall, 60% and 43.4% of patients exhibited diffuse paresthesia and burning pain later after
218 the initial presentation (**Figure 1A**). The DN4 questionnaire screening neuropathic pain was
219 positive ($\geq 4/10$) for 50% (15/30) of patients and the FiRST questionnaire screening for
220 fibromyalgia-like symptoms was positive ($\geq 5/6$) for 56.6% (17/30; **supplementary figure**
221 **1**).

222 The clinical examination including neurological examination was unremarkable. At this time,
223 no patients received corticosteroids, non-steroidal anti-inflammatory drugs or opioids.
224 Finally, 16 (53.3%) patients reported a trend toward a decrease of symptoms over time.

225

226 *Virologic and specific immunologic evaluation*

227 Specific analyses related to SARS-CoV-2 infection were conducted at a median of 174 days
228 (IQR 144-215) after symptom onset. At this time, in 18 (60%) and 6 (20%) of patients
229 underwent nasopharyngeal and stool RT-PCR for SARS-CoV-2; all tests were negative.

230 Exploration of the cellular immune response by SARS-CoV-2 IFN- γ ELISPOT assay
231 revealed that 15 (50%) patients had a positive response to at least SARS-CoV-2 nucleocapsid

232 and spike proteins (considered ELISPOT-positive, **Figure 2A**). Among ELISPOT-positive
233 patients, 73.3% (11/15) also had a cellular response against non-structural SARS-CoV-2 as
234 compared with only 1 (6.7%) of ELISPOT-negative patients ($p < 0.0001$). Cellular response
235 to the spike protein of human coronavirus 229E and OC43 was similar in both SARS-CoV-2
236 ELISPOT groups (E+100% vs E- 86.7% and E+ 80% vs E- 73.3%).

237 Among patients with a negative IFN- γ ELISPOT result, all but one had negative serology
238 results (**Figure 2A**). This patient had an isolated anti-S IgG assay. Among the 15 patients
239 with a positive IFN- γ ELISPOT result, all had at least one positive serological assay. In
240 detail, 14 (93.3%) had a positive result for anti-RBD total antibodies, 11 (73.3%) anti-RBD
241 IgG/IgM, 12 (80%) anti-S IgG and 11 (73.3%) anti-N IgG (**Figure 2A**). We dichotomized the
242 patients into an immunized group (ELISPOT-positive and at least one positive serological
243 assay, $n = 15$) and a non-immunized group (ELISPOT-negative, $n = 15$; **Figure 2B**), with
244 little difference in terms of symptoms (**Figure 1B**).

245 One ELISPOT-positive patient showed a decreasing signal for anti-N (equivocal to negative)
246 and anti-S signal (positive to equivocal) between day 133 and day 251. Additionally, one
247 patient with negative results for both IFN- γ ELISPOT and serology assays (conducted 140
248 days after symptom onset) previously had a positive nasopharyngeal RT-PCR SARS-CoV-2
249 result early after the first symptoms (**Figure 2B**). This patient also had 2 negative IgG
250 serology tests for SARS-CoV-2 at 37 and 85 days after symptom onset (Biosynex ICT and
251 CLIA Cobas Roche, respectively).

252 IFN- $\alpha 2$ levels were similar for patients with persistent symptoms (regardless of their
253 immunity status) and those with a history of documented COVID-19 free of residual
254 symptoms (sampled > 12 weeks after infection; **Figure 3**). Other cytokine levels were low or
255 non-detectable and were similar between patients with and without immunization for SARS-
256 CoV-2 (**Supplementary figure 2**).

257

258 *Biological evaluation*

259 Biological analyses (**supplementary file 1**) were conducted at the same time as the clinical
260 evaluation (152 days [IQR 102-164] after initial presentation). Routine biological test results
261 were within normal limits for all but one patient (an iron-deficiency anemia that was further
262 investigated and corrected). Values for markers of cardiac and muscle injury (troponin and
263 creatine phosphokinase) and coagulopathy (D-dimers, fibrinogen) were normal, and serology
264 for HIV, hepatitis C virus and Lyme disease was negative for all patients.

265 Screening for autoimmunity revealed low (1/160) and medium (1/320 to 1/640) titers of anti-
266 nuclear antibodies in 12 and 3 patients, respectively. Low to medium anti-nuclear antibody
267 titers were numerically more prevalent in SARS-CoV-2 immunized than non-immunized
268 patients (66.7% vs 33.3%, $p = 0.067$). Screening for anti-extractable nuclear antigens, anti-
269 double-stranded DNA, anti-citrullinated protein and anti-neutrophil cytoplasmic antibodies as
270 well as rheumatoid factor was negative for all patients. Eight patients (4 in each
271 immunization group) showed isolated low titers (< 3 times normal range) of anti-cardiolipin
272 antibodies, with no history of thrombosis (IgM for 6, IgG for 2), and one patient was positive
273 for lupus anticoagulant. After 12 weeks, the repeat antiphospholipid antibodies testing was
274 negative for all patients.

275

276 *Psychological evaluation*

277 The phone interview by a clinical psychologist took place after a median of 224 days [202-
278 238] after initial symptom onset. In all, 10% (3/30) and 26.7% (8/30) of patients had a history
279 of depression and anxiety disorders, respectively. Sleep issues were reported by 23 (73.3%)
280 patients, and 4 (13.3%) had started an anxiolytic prescriptions (**Table 2**); 5 (16.7%) and 7
281 (23.3%) reported loss of employment and financial difficulties.

282 HADS screening for anxiety and depression was positive for 11 (36.7%) and 13 (43.3%) of
283 patients, respectively (**Table 2**). Using the PCL-5 questionnaire, 9 (30%) patients had scores
284 compatible with PTSD (**Table 2**). These values did not differ by immunization status (**Figure**
285 4). Several components of the SF-36 scale, physical limitations, energy and pain, were
286 severely affected, with no significant difference between patients immunized or not for
287 SARS-CoV-2 (**supplementary figure 3**). Family, friends and colleagues were a major source
288 of support for 20 (66.7%), 18 (60%) and 11/25 (44%) patients, respectively. Conversely, 7
289 (23.3%) patients felt significant support by physicians.

290

291 **Discussion**

292 In this study, we included 30 consecutive patients seeking medical help for persistent
293 symptoms (median 6 months) self-attributed to COVID-19. We identified two clinically
294 comparable groups of long-COVID: those with and those without objective SARS-CoV-2
295 immunity. In 93% of patients, persistent symptoms had a cyclical pattern and were mostly
296 represented by fatigue, thoracic oppression, myalgia, paresthesia and burning pain, which
297 agrees with the literature (20,21). Dichotomizing patients by presence or not of anti-SARS-
298 CoV-2 immunity resulted in only small differences in clinical presentation (**Figure 1B**).
299 Indeed, both groups had high pain/fatigue indexes and limitations in several components of
300 the SF-36 scale (**Supplemental Figures 1 and 3**).

301 Only half of the patient had objective cellular (IFN- γ ELISPOT-based) and humoral
302 immunity for SARS-CoV-2 (**Figure 2B**). There are three possible (and non-exclusive)
303 explanations for this result. First, some patients may have been infected with SARS-CoV-2,
304 without detectable immunity. As already described (22), one of our patients with RT-PCR-
305 proven SARS-CoV-2 infection had a negative SARS-CoV-2 serology result at several times
306 (36, 85 and 140 days after initial symptoms) as well as on IFN- γ ELISPOT (after 140 days).
307 Second, immunity may have developed in some patients but subsequently waned over time,
308 although such reports are discordant (23,24). In our cohort, one patient with PCR/ELISPOT-
309 confirmed infection showed IgG serology findings between days 133 and 251, both on anti-N
310 (from equivocal to negative) and anti-S (from positive to equivocal) ELISA. Additionally,
311 patients with cellular immunity might have negative serology, particularly anti-N IgG
312 (**Figure 2A**). Finally, some patients may have presented a non-specific viral illness and
313 subsequent symptoms, which were falsely attributed to SARS-CoV-2. In fact, the period of
314 the first pandemic wave was highly anxiogenic and may have exacerbated pre-existing
315 psychological conditions and induced a nocebo effect in some patients (25).

316 The high prevalence of probable anxiety and depression disorders (36.7% and 43.3%
317 respectively) are striking. A cohort study in the United Kingdom revealed that the incidence
318 of probable anxiety and depression disorder in the general population was 24% and 18.1%
319 during the pandemic (26). A history of reported COVID-19 was associated with increased
320 risk anxiety and depression. We also highlighted a high rate of probable PTSD (33.3%),
321 which is similar to the 30.8% prevalence in a US study (27). PTSD reflects the hardship of
322 the patient's experience with COVID-19. The persistence of physical symptoms (related or
323 not to COVID-19) is likely associated with the psychological burden of the pandemic,
324 synergistically contributing to the emergence of "long-COVID", and may explain the high
325 prevalence of psychological disorders in our cohort.

326 Long-COVID is an ill-defined condition characterized by symptoms persisting for at least 4
327 to 12 weeks after SARS-CoV-2 infection, depending on the study (10,13). Excluding
328 alternate diagnoses is crucial because objective evidence of previous COVID-19 may not be
329 mandatory for the diagnosis of long-COVID (13,20). Deep phenotyping of our patients did
330 not lead to alternative diagnoses in all patients. Long-COVID mainly represents patients with
331 non-severe initial presentations (12), and its pathophysiology is likely multifactorial. For non-
332 hospitalized long-COVID patients, physical deconditioning (28), psychological disorders
333 (29), viral encephalitis (7), dysautonomia (30), and immunological abnormalities are
334 plausible suspects and could co-exist. Indeed, auto-immunity has been demonstrated
335 following COVID-19 (31,32). However, viral-induced autoimmunity is likely transient, as
336 demonstrated by the negative repeat screening for antiphospholipid antibodies in 8 initially
337 positive patients, as well as the lack of significant increase in cytokine/IFN- α 2 levels and
338 clinical/biological signs of autoimmune disease. Further studies will need to explore other
339 potential mechanisms at play in such patients (*e.g.*, dysautonomia, neurological studies).

340 This study has limitations. First, we included 30 consecutive patients, which may not allow to
341 capture the complexity of long-COVID. However, this number allowed for a multimodal
342 evaluation without missing data, and the consecutive recruitment limited potential selection
343 bias. Given our study design, we cannot infer the prevalence of long-COVID, which has been
344 evaluated at 10% in the United Kingdom (10). Only 9 patients had a RT-PCR test in our
345 cohort in the 5 weeks after symptom onset, because RT-PCR tests were not available for mild
346 diseases during the first epidemic wave in France. Finally, we cannot exclude that our design
347 implied a selection bias of patients with psychological distress. However, our study allowed
348 for accurately evaluating the patients seeking medical advice for persistent symptoms self-
349 attributed to long-COVID and will therefore be of use for clinicians who may be under-
350 prepared to answer these patients' questions. Although no treatment has been approved for
351 long-COVID, more than half of our patients reported a spontaneous and gradual
352 improvement of symptoms over time, which provides a window of hope for these patients.
353 To conclude, our study sheds light on the burden experienced by patients reporting long-term
354 symptoms self-attributed to COVID-19, as well as some of the mechanisms at play. A better
355 recognition and understanding of long-COVID will help healthcare providers care for these
356 patients.

357
358

359 **References**

360

- 361 1. Carfi A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care
362 Study Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA*. 11 août
363 2020;324(6):603.
- 364 2. Living with Covid19 [Internet]. National Institute for Health Research; 2020 oct [cité 13
365 nov 2020]. Disponible sur: [https://evidence.nihr.ac.uk/themedreview/living-with-](https://evidence.nihr.ac.uk/themedreview/living-with-covid19/)
366 [covid19/](https://evidence.nihr.ac.uk/themedreview/living-with-covid19/)
- 367 3. Covid Long Haulers Describe the Devastating Aftereffects of the Disease.
368 Bloomberg.com [Internet]. 9 nov 2020 [cité 5 déc 2020]; Disponible sur:
369 [https://www.bloomberg.com/news/features/2020-11-09/coronavirus-long-haulers-tell-](https://www.bloomberg.com/news/features/2020-11-09/coronavirus-long-haulers-tell-us-their-symptoms-and-the-aftereffects-of-disease)
370 [us-their-symptoms-and-the-aftereffects-of-disease](https://www.bloomberg.com/news/features/2020-11-09/coronavirus-long-haulers-tell-us-their-symptoms-and-the-aftereffects-of-disease)
- 371 4. Long Covid: 'Is this now me forever?' [Internet]. the Guardian. 2020 [cité 5 déc 2020].
372 Disponible sur: [http://www.theguardian.com/world/2020/nov/29/eleanor-morgan-is-](http://www.theguardian.com/world/2020/nov/29/eleanor-morgan-is-still-struggling-with-long-covid-months-after-catching-the-virus)
373 [still-struggling-with-long-covid-months-after-catching-the-virus](http://www.theguardian.com/world/2020/nov/29/eleanor-morgan-is-still-struggling-with-long-covid-months-after-catching-the-virus)
- 374 5. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of
375 Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA*
376 *Cardiol*. 1 juill 2020;5(7):811.
- 377 6. Salehi S, Reddy S, Gholamrezanezhad A. Long-term Pulmonary Consequences of
378 Coronavirus Disease 2019 (COVID-19): What We Know and What to Expect. *J Thorac*
379 *Imaging*. juill 2020;35(4):W87-9.
- 380 7. Pero A, Ng S, Cai D. COVID-19: A Perspective from Clinical Neurology and
381 Neuroscience. *The Neuroscientist*. oct 2020;26(5):387-91.
- 382 8. Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes
383 Among Patients Hospitalized With COVID-19. *Ann Intern Med* [Internet]. 11 nov 2020
384 [cité 13 nov 2020]; Disponible sur: <https://www.acpjournals.org/doi/10.7326/M20-5661>
- 385 9. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of
386 COVID-19 in patients discharged from hospital: a cohort study. *The Lancet*. 16 janv
387 2021;397(10270):220-32.
- 388 10. Prevalence of long COVID symptoms and COVID-19 complications - Office for
389 National Statistics [Internet]. [cité 16 déc 2020]. Disponible sur:
390 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandl](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/datasets/prevalenceoflongcovidssymptomsandcovid19complications)
391 [ifeexpectancies/datasets/prevalenceoflongcovidssymptomsandcovid19complications](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/datasets/prevalenceoflongcovidssymptomsandcovid19complications)
- 392 11. Yelin D, Wirtheim E, Vetter P, Kalil AC, Bruchfeld J, Runold M, et al. Long-term
393 consequences of COVID-19: research needs. *Lancet Infect Dis*. 1 oct
394 2020;20(10):1115-7.
- 395 12. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing
396 Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact.
397 medRxiv. 27 déc 2020;2020.12.24.20248802.

- 398 13. Raveendran AV. Long COVID-19: Challenges in the diagnosis and proposed diagnostic
399 criteria. *Diabetes Metab Syndr Clin Res Rev.* janv 2021;15(1):145-6.
- 400 14. Salje H, Kiem CT, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the
401 burden of SARS-CoV-2 in France. *Science.* 10 juill 2020;369(6500):208-11.
- 402 15. Cruccu G, Sommer C, Anand P, Attal N, Baron R, Garcia-Larrea L, et al. EFNS
403 guidelines on neuropathic pain assessment: revised 2009: Neuropathic pain assessment.
404 *Eur J Neurol.* août 2010;17(8):1010-8.
- 405 16. Perrot S, Bouhassira D, Fermanian J. Development and validation of the Fibromyalgia
406 Rapid Screening Tool (FiRST): *Pain.* août 2010;150(2):250-6.
- 407 17. Rodero MP, Decalf J, Bondet V, Hunt D, Rice GI, Werneke S, et al. Detection of
408 interferon alpha protein reveals differential levels and cellular sources in disease. *J Exp*
409 *Med.* 1 mai 2017;214(5):1547-55.
- 410 18. Roberge P. A psychometric evaluation of the French Canadian version of the Hospital
411 Anxiety and Depression Scale in a large primary care population. *J Affect Disord.*
412 2013;9.
- 413 19. Bovin MJ, Marx BP, Weathers FW, Gallagher MW, Rodriguez P, Schnurr PP, et al.
414 Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of
415 Mental Disorders–Fifth Edition (PCL-5) in veterans. *Psychol Assess.* nov
416 2016;28(11):1379-91.
- 417 20. Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute
418 covid-19 in primary care. *BMJ.* 11 août 2020;m3026.
- 419 21. Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al. Persistent
420 symptoms after Covid-19: qualitative study of 114 “long Covid” patients and draft
421 quality principles for services. *BMC Health Serv Res.* 20 déc 2020;20(1):1144.
- 422 22. Schwarzkopf S, Krawczyk A, Knop D, Klump H, Heinold A, Heinemann FM, et al.
423 Early Release - Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed
424 Infection but with Undetectable SARS-CoV-2-Specific IgG - Volume 27, Number 1—
425 January 2021 - *Emerging Infectious Diseases journal - CDC.* [cité 24 nov 2020];
426 Disponible sur: https://wwwnc.cdc.gov/eid/article/27/1/20-3772_article
- 427 23. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al.
428 Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. *N Engl*
429 *J Med.* 10 sept 2020;383(11):1085-7.
- 430 24. Tonn T, Corman VM, Johnsen M, Richter A, Rodionov RN, Drosten C, et al. Stability
431 and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma.
432 *Lancet Microbe.* 1 juin 2020;1(2):e63.
- 433 25. Amanzio M, Howick J, Bartoli M, Cipriani GE, Kong J. How Do Nocebo Phenomena
434 Provide a Theoretical Framework for the COVID-19 Pandemic? *Front Psychol.* 30 oct
435 2020;11:589884.

- 436 26. Kwong ASF, Pearson RM, Adams MJ, Northstone K, Tilling K, Smith D, et al. Mental
437 health before and during COVID-19 in two longitudinal UK population cohorts. *Br J*
438 *Psychiatry*. 24 nov 2020;177:27.
- 439 27. Liu CH, Zhang E, Wong GTF, Hyun S, Hahm H “Chris”. Factors associated with
440 depression, anxiety, and PTSD symptomatology during the COVID-19 pandemic:
441 Clinical implications for U.S. young adult mental health. *Psychiatry Res*. août
442 2020;290:113172.
- 443 28. Covid-19 will be followed by a deconditioning pandemic [Internet]. *The BMJ*. 2020
444 [cité 3 janv 2021]. Disponible sur: [https://blogs.bmj.com/bmj/2020/06/15/covid-19-will-](https://blogs.bmj.com/bmj/2020/06/15/covid-19-will-be-followed-by-a-deconditioning-pandemic/)
445 [be-followed-by-a-deconditioning-pandemic/](https://blogs.bmj.com/bmj/2020/06/15/covid-19-will-be-followed-by-a-deconditioning-pandemic/)
- 446 29. Butler M, Pollak TA, Rooney AG, Michael BD, Nicholson TR. Neuropsychiatric
447 complications of covid-19. *BMJ*. 13 oct 2020;371:m3871.
- 448 30. Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, et al.
449 Autonomic dysfunction in ‘long COVID’: rationale, physiology and management
450 strategies. *Clin Med [Internet]*. 26 nov 2020 [cité 2 janv 2021]; Disponible sur:
451 <https://www.rcpjournals.org/content/clinmedicine/early/2020/11/26/clinmed.2020-0896>
- 452 31. Wang EY, Mao T, Klein J, Dai Y, Huck JD, Liu F, et al. Diverse Functional
453 Autoantibodies in Patients with COVID-19 [Internet]. *Infectious Diseases (except*
454 *HIV/AIDS)*; 2020 déc [cité 3 janv 2021]. Disponible sur:
455 <http://medrxiv.org/lookup/doi/10.1101/2020.12.10.20247205>
- 456 32. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al.
457 Autoantibodies against type I IFNs in patients with life-threatening COVID-19. *Science*
458 [Internet]. 23 oct 2020 [cité 3 janv 2021];370(6515). Disponible sur:
459 <https://science.sciencemag.org/content/370/6515/eabd4585>

460
461

462 **Authors contributions :**


463 MS, RF, JS, EC and LP recruited and evaluated clinically the patients. FG, CN and SFK
464 conducted the virological evaluations. AM, AG and PV participated in the psychiatric
465 evaluation. RAM conducted the psychological evaluation. SBT, RC, STA, MP, AB and SB
466 conducted the immunological assays (cytokines). LA, JEG helped in the design of the study
467 and critically reviewed the manuscript. MS, RF, FG, RFK and JS wrote the manuscript.
468 MS, RF and FG are co-first authors. RFK and JS are co-last authors.

469

470 **Funding source :**

471 None to disclose.

472




473
474
475
476
477
478
479
480
481
482
483
484

Figure 1: Initial and residual clinical features of patients with persistent symptoms self-attributed to COVID-19.

(A) Residual symptoms collected at a median of 152 days [interquartile range (IQR) 102-164] after initial presentation (n = 30 patients). Columns indicate symptom prevalence and bars are mean ± standard error measure. P-values were calculated with McNemar's test with Bonferroni correction for multiple analysis.

(B) Comparison of initial/residual symptoms between immunized and non-immunized patients. Columns indicate symptom prevalence in immunized (defined by ELISA or serology; red) and non-immunized patients; bars are mean ± standard error measure. *p < 0.05 by chi-square or Fisher's exact test (if appropriate).




485
486
487
488
489
490
491
492
493
494
495
496

Figure 2: Specific immunological responses to SARS-CoV-2 in 30 patients reporting persistent symptoms self-attributed to long-COVID.

- (A) Results of SARS-CoV-2 serologic assays based on the interferon- γ (IFN- γ) ELISPOT-results ($n = 15$ /group). Anti-RBD total antibody (Wantai total antibody); anti-RBD IgG/IgM (Biosynex BSS IgM/IgG assay); anti-S IgG (Euroimmun); anti-N IgG (Abbott Architect). Data are mean \pm standard error measure prevalence of test positivity.
- (B) Two patterns of patients were identified: those with objective signs of SARS-CoV-2 immunity (cellular and humoral response, $n = 15$) and those without ($n = 15$). Positive IgG was defined as a positive result against spike, receptor binding domain or nucleocapsid protein.


497 *, *One patient with virologically unproven initial presentation had an isolated anti-S*
498 *IgG–positive assay result. IFN- γ ELISPOT and all other serological tests were*
499 *negative.*
500 #, *One with a virologically-proven initial presentation had negative SARS-CoV-2*
501 *ELISPOT (conducted at day 140) and serological assays (conducted at days 37, 85*
502 *and 140).*

503
504



505
506 **Figure 3: Normal levels of IFN- α 2 for patients with persistent symptoms attributed to**
507 **COVID-19.** Ultra-sensitive IFN- α levels were measured by using SIMOA in patients with
508 persistent symptoms self-attributed to COVID-19. As a comparison, IFN- α 2 levels of
509 individuals with confirmed previous COVID-19 (serology and IFN- γ positive) without
510 persistent symptoms (sampled at least 12 weeks after; n = 17) and patients with active
511 systemic lupus erythematosus (n = 18). Each point corresponds to a single patient; the
512 central bar shows medians with interquartile ranges. The red dotted line shows the lower
513 limit of detection. ns, non-significant; ***, p < 0.001 versus all other groups by non-
514 parametric Kruskal-Wallis test with Dunn's correction for multiple testing.
515

516



517

518

519

520

521

Figure 4: Prevalence of anxiety/depression disorders and post-traumatic stress syndrome in patients seeking medical help for persistent symptoms self-attributed to COVID-19. Data are mean \pm standard error measure prevalence.

522 **Table 1: Characteristics of the whole population and patients with or without cellular**
 523 **and/or humoral immunization.**
 524

Characteristics	Total population (n = 30)	Immunized (n = 15)	Non-immunized (n = 15)	p-value
Demographics				
Age (median, IQR)	40 [35-54]	40 [31-58]	39 [35-45]	<i>ns</i>
Female sex	60% (18)	46.7% (7)	73.3 (11)	<i>0.14</i>
Close contact with confirmed COVID-19 patients	43.3% (13/30)	46.7% (7/15)	40% (6/15)	<i>ns</i>
Risk factors for severe SARS-CoV-2 infection (history of)				
BMI (kg/m ²), (median, IQR)	22.6 [20.4-26.3]	23.6 [21.2-27.8]	22.4 [19.6-24.5]	<i>ns</i>
> 25	30% (9)	40%	20%	
> 30	20% (6)	26.7%	13.3%	
Diabetes	10% (3)	13.3% (2)	6.7% (1)	<i>ns</i>
Hypertension	3.3% (1)	6.7% (1)	0%	<i>ns</i>
Myocardial infarction	0%			<i>ns</i>
Cerebrovascular event	6.7% (1)	13.3% (2)	0%	<i>ns</i>
Respiratory disease	0%			<i>ns</i>
Renal failure	0%			<i>ns</i>
Liver failure	0%			<i>ns</i>
Cancer	3.3% (1)	6.7% (1)	0%	<i>ns</i>
Smoking				
History	43.3% (13)	53.3% (8)	33.3% (5)	<i>ns</i>
Active	3.3% (1)	0%	6.7% (1)	
Socio-economic				
Married	28.6%	30.8%	26.7%	<i>ns</i>
Working status				
Currently working	83.3%	66.7%	100%	<i>ns</i>
Unemployed	10%	20%	0%	
Retired	6.67%	13.3%	0%	
Education level				
Below high school	6.7%	13.3%	0%	<i>ns</i>
High school	16.7%	26.7%	6.7%	
≤3 years post-high school	26.7%	13.3%	40%	
College graduate	50%	46.7%	53.3%	

525 BMI, body mass index; ns, not significant

526

527


528

529


530 **Table 2: Psychological evaluation of the whole population and patients with and without**
 531 **cellular and/or humoral immunization.**
 532

Psychological evaluation	Total population (n =30)	Immunized (n = 15)	Non-immunized (n = 15)	p-value
History				
Depression disorder	10% (3)	6.7% (1)	13.3% (2)	<i>ns</i>
Anxiety disorder	26.7% (8)	26.7% (4)	26.7% (4)	<i>ns</i>
Context				
Loss of job due to pandemic	16.7% (5)	20% (3)	13.3% (2)	<i>ns</i>
Financial difficulties	23.3% (7)	20% (3)	26.7% (4)	<i>ns</i>
Death of close-ones due to COVID-19	0%			
Symptoms				
Sleep issues	76.7% (23)	80% (12)	73.3% (11)	<i>ns</i>
Use of anxiolytics	13.3% (4)	20% (3)	6.7% (1)	<i>ns</i>
Increased alcohol/tobacco use after diagnosis	6.7% (2)	13.3% (2)	0%	<i>ns</i>
Probable anxiety disorder (HADS-A ≥ 10)	36.6% (11)	33.3% (5)	40% (6)	<i>ns</i>
Probable depression disorder (HADS-D ≥ 7)	43.3% (13)	46.6% (7)	40% (6)	<i>ns</i>
Probable post-traumatic stress syndrome (PCL-5 ≥ 31)	30% (9)	33.3% (5)	26.7% (4)	<i>ns</i>
Patients' perception* (N = 29)				
COVID-19 is dangerous	79.3% (23)	85.7 (12)	73.3% (11)	<i>ns</i>
COVID-19 pandemic is worrisome	41.4% (12)	35.7% (5)	46.7% (7)	<i>ns</i>
Support from family	66.7% (20)	73.3% (11)	60% (9)	<i>ns</i>
Support from friends	60% (18)	73.3% (11)	46.7% (7)	<i>ns</i>
Support from colleagues	44% (11/25)	36.4% (4/11)	50% (7/14)	<i>ns</i>
Support from physicians	20.7% (6)	28.6% (4)	13.3% (2)	<i>ns</i>
Good acknowledgment from the media	10.3% (3)	21.4% (3)	0%	<i>0.10</i>
Good management of pandemics by the authorities	20.7% (6)	35.7% (5)	6.7% (1)	<i>0.08</i>

533 *, answers were recorded on a 1-5 scale, and positivity was considered with score ≥ 4
 534 HADS, Hospital Anxiety and Depression Scale; A, anxiety; D, depression




535
 536 *Supplementary figure 1: Comparison of pain, fatigue, dryness scores, DN4 and FiRST and*
 537 *Health Assessment Questionnaire (HAQ) scores in patients seeking medical help for*
 538 *persistent symptoms self-attributed to COVID-19. For continuous variables, data are*
 539 *median and interquartile range. For binary variables (DN4 and FiRST), data are mean ±*
 540 *standard error measure prevalence of positivity. VAS, visual analog scale; FiRST,*
 541 *Fibromyalgia Rapid Screening Tool*
 542



543
544
545
546
547
548

Supplementary figure 2: Cytokine levels in patients long-COVID patients compared to asymptomatic convalescent COVID-19 and acute severe COVID-19. Data are median and bars indicate interquartile range.



549
550
551
552

*Supplementary figure 3: Components of the Medical Outcomes Study 36-item Short-form (SF-36) scale. Lower scores indicate worse health. Data are median and bars indicate interquartile range. *, $p < 0.05$ by Mann-Whitney test.*

553

554 **Supplementary file 1: Systematic bloodwork of long-COVID patients.**

555

- 556 - Hemogram
- 557 - Ionogram, calcium, phosphorus, creatinine, urea, angiotensin-converting enzyme
- 558 - Creatine phosphokinase, troponin I
- 559 - Plasma protein electrophoresis and immunofixation
- 560 - Urine protein and creatinine
- 561 - TSH, 25 OH vitamin D, PTH
- 562 - TP, TCA, INR, D-dimers, fibrinogen
- 563 - Anti-nuclear antibodies (if $\geq 1/360$: Extractable nuclear antibody and anti-double-
- 564 stranded DNA were screened), rheumatoid factor, anti-citrullinated protein antibodies
- 565 (ACPA using CCP2), ANCA, anti-cardiolipin, anti-beta-2 glycoprotein 1 antibodies
- 566 and lupus anticoagulant.
- 567 - IgG, IgA, IgM levels
- 568 - C3-C4 and CH50
- 569 - HIV, HBV, HCV, CMV, EBV and Lyme (ELISA then western blot if positive)
- 570 serology